CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Conditions: Autoimmune Hemolytic Anemia; Autologous CD19 CAR-T; Failure of Three or More Lines of Therapy Interventions: Biological: CNCT19 CAR-T cell therapy Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Juventas Cell Therapy Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06231368

Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials